Which stocks are experiencing notable movement on Tuesday? Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Let's uncover which stocks are experiencing notable gaps during today's session. Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data Atai and Beckley report that a single dose of BPL-003 reduced depression symptoms significantly and safely in treatment-resistant patients.
Get insights into the top gainers and losers of Tuesday's pre-market session. Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.
Atai Life Sciences Stock Soars To 3-Month High As Depression Study Yields Promising Results: Retail Bulls Cheer Atai Life Sciences shares surged 11.4% after Beckley Psytech reported encouraging Phase 2a results of its depression treatment
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.
Wondering what's happening in today's after-hours session? Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care? AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care.
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position.
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential.
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options.
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are having growing pains.
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a Portfolio of the 4 largest such companies.
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
